BEVERLY, Mass. USA – October 26, 2021 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing for veterinary diagnostics, today announced it has been selected as a Best in Show Spotlight company at the Petcare Innovation Summit to be held in Boston, MA in early December.
Dr. Jack Regan, LexaGene’s CEO and Founder stated, “It is an honor to have LexaGene selected amongst the many applicants. I’m pleased the selection committee recognized how innovative and revolutionary the MiQLab System is for the veterinary industry. The MiQLab allows for in-hospital evidence-based decision making so antimicrobials are only prescribed when necessary and are appropriately selected. I’m excited to have LexaGene lead the way to promote a new wave of diagnostic testing for the veterinary market. This speaking engagement gives the Company the opportunity to speak directly to industry leaders as well as investors focused on funding innovative life sciences companies.”
Start-ups and emerging pet care brands are invited to the Petcare Innovation Summit where introductions can accelerate growth, strengthen the investment pipeline, and expose brands to executives who are looking for game-changers within the industry.
According to the Summit organizers:
- More than 110 billion U.S. dollars will be spent in the pet industry in 2021.
- More than 65 percent of all U.S. families own a pet.
- During the COVID-19 pandemic, nearly one in three Americans adopted a pet.
- Millennials now represent the biggest share of pet owners in the U.S.
Dr. Regan continued, “The veterinary industry is booming and we’re not seeing any indication of it slowing down. Most veterinarians are overwhelmed by the flood of new pets from pandemic-fueled adoptions and LexaGene’s MiQLab system offers these veterinarians a much more efficient way to diagnose and treat animals – which will minimize the number of return visits due to unresolved infections.”
The 47th Annual Petcare Innovation Summit will be held in Boston, MA, on December 7-8 at the Hilton Back Bay Hotel. To register for the conference, visit their website.
LexaGene’s MiQLab System is designed for in-clinic use and screens for common bacterial infections and antimicrobial resistance factors, returning results in ~ 2 hours versus multiple days for laboratory-based results.
On Behalf of the Board of Directors
Dr. Jack Regan
Chief Executive Officer & Chairman
Corporate & Media Contact:
Director of Marketing
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing, and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The MiQLab™ system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.